China’s pharmaceutical industry has moved from the sidelines to become a headline export in the country’s new “New New Three” – robots, artificial intelligence and cutting‑edge medicines. A Health Affairs study released on July 20, 2026 shows that between 2020 and 2025 China approved 94 new anticancer drugs, beating the United States’ 87 approvals and outpacing it three‑fold in 2025. While most of those drugs were already on the market abroad, the sheer volume signals a shift from a generic‑focused past to a home‑grown innovation engine. Just days later, China’s regulator approved Opiprandil tablets – the first drug ever submitted to the NMPA and cleared there – for a rare form of narcolepsy, a moment hailed as a “Chinese moment” in global drug development. Multinational giants such as Pfizer and GSK are now striking multibillion‑dollar licensing deals with Chinese firms, eager to tap the country’s fast‑growing pipeline as a wave of patent expirations threatens their own revenues. Behind the deals, China has overhauled its regulatory system: reviewers have quadrupled, average review times for innovative drugs fell from 175 days in 2017 to 50 days in 2024, and the nation joined the International Council for Harmonisation, aligning its standards with the world’s best. Though most Chinese oncology drugs remain follow‑on products with a modest global market share, the maturing CRO/CMO ecosystem and new overseas subsidiaries are laying the groundwork for true breakthrough discoveries. The pharma sector’s transformation from imitation to innovation is now a key driver of China’s export renaissance.
Read moreChina is fast becoming a world leader in cell and gene therapy, thanks to a surge of more than 100,000 companies racing to develop new treatments. At a recent health conference, Li Qijing of Singapore’s A*STAR praised China’s breakthroughs in both lab methods and real‑world applications, especially a new approach called in‑vivo CAR‑T. Unlike traditional CAR‑T, which requires doctors to extract a patient’s immune cells, re‑engineer them in a lab, and then infuse them back, in‑vivo CAR‑T turns the body’s own T‑cells into cancer‑fighting agents with a simple IV injection. This shortcut slashes manufacturing time and costs dramatically, making the therapy cheaper and more scalable. Investors are taking notice. Songhe Capital reports that nearly $5 billion has poured into in‑vivo CAR‑T projects worldwide for 2025, and the technology is already cutting production expenses and speeding up delivery. Yet challenges remain. No cell‑therapy product priced between 100,000 and 200,000 yuan has yet received Chinese approval, and the path from research to market is long, capital‑intensive, and fraught with regulatory hurdles. The government is tightening oversight of the sprawling “gray” industry, where many firms operate with minimal supervision. With over 149,000 cell‑medicine companies registered and nearly 34,000 new entrants in 2025 alone, the sector’s growth is undeniable—but turning that momentum into affordable, widely‑available anti‑aging treatments will require sustained innovation, clear regulations, and steady financing.
Read moreThe Zhangjiang Pharmaceutical Valley hosted a high‑profile conference that gathered top scientists, industry leaders and policymakers to map the future of stem‑cell medicine in China. Academician Gao Shaorong highlighted how pluripotent stem cells could shift the country from following global trends to setting them. New government policies (decrees 818 and 828) were dissected by experts, showing how they will boost investment, streamline approvals and reduce compliance risks for biotech firms. Key takeaways included: cutting‑edge exosome research for anti‑aging products; a step‑by‑step roadmap for turning lab discoveries into market‑ready stem‑cell therapies; and the rise of a “longevity economy” that blends stem‑cell tech with health‑care business models. Data‑driven precision medicine was emphasized as the engine for clinical translation, while breakthroughs in universal organ‑transplant strategies promise to ease donor shortages. Highlights also covered heart‑repair cells derived from human pluripotent stem cells, innovative mitochondrial‑rescue therapies for metabolic disease, and the growing role of stem‑cell‑derived drugs in treating kidney, liver and infectious diseases. The summit painted a vivid picture of a rapidly maturing ecosystem—moving from research labs to factories, hospitals and global markets—underpinned by strong policy support and a clear push toward standardization and international collaboration.
Read more